吸入布地奈德治疗支气管扩张伴喘息的临床观察

Clinical observation of inhaled budesonide in patients with bronchiectasis and asthma

目的观察吸入布地奈德治疗支气管扩张伴喘息的疗效和安全性。方法 39例支气管扩张伴喘息患者随机分为治疗组和对照组,对照组18例仅行常规治疗,治疗组21例在常规治疗基础上行布地奈德吸入治疗。观察治疗前后及出院后3个月的肺功能、PO2、症状计分、喘息发作频率等。结果治疗组治疗后及出院后3个月第1秒用力呼气容积(FEV1)、PO2明显高于对照组(P<0.01),而症状计分明显减少下降(P<0.01)。出院后3个月,治疗组患者喘息发作频率积分高于对照组(P<0.05)。结论布地奈德吸入治疗可改善支气管扩张伴喘息的肺通气功能、临床症状和喘息发作频率。

Objective To observe the therapeutic efficacy and safety of inhaled budesonide in patients with bronchiectasis and asthma. Methods Thirty-nine patients with bronchiectasis and asthma were randomly divided into treatment and control groups. Control group only received conventional therapy, while treatment group adopted additional budesonide inhalation. The pulmonary function, PO2, and symptom and asthma scores were evaluated in both groups before and after therapy and 3 months out of hospital. Results Compared with control group, FEV1 and PO2 were higher （P〈0.01）, but symptom score was lower （P〈0.01） in treatment group after therapy and 3 months after discharge. The asthma score in treatment group was superior to that in control group （P〈0.05）. Conclusion Budesonide inhalation can improve pulmonary function, clinical symptoms and asthma score in patients with bronchiectasis and asthma.